Reuters logo
BRIEF-Celgene announces positive results from radiance
May 22, 2017 / 11:45 AM / 6 months ago

BRIEF-Celgene announces positive results from radiance

May 22 (Reuters) - Celgene Corp:

* Celgene announces positive results from radiance, the second pivotal phase III trial of oral ozanimod in patients with relapsing multiple sclerosis

* Celgene announces positive results from radiance, the second pivotal phase iii trial of oral ozanimod in patients with relapsing multiple sclerosis

* Says study met primary endpoint

* Celgene Corp says new drug application submission to U.S. Food and Drug Administration planned by end of 2017

* Celgene Corp says safety and tolerability consistent with prior phase II and III studies in the study

* Says further analyses of radiance trial are ongoing

* Says plan to begin submitting global registration dossiers by end of year

* Celgene Corp says both doses of ozanimod demonstrated statistically significant reductions in brain atrophy compared to Avonex in each phase III trial Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below